CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS Russian patent published in 2023 - IPC C07K16/28 C12N15/13 C12N15/63 A61K39/395 A61P35/00 

FIELD: biopharmaceuticals.

SUBSTANCE: invention is related to an antibody targeting CD3, a bispecific antibody, their production and use. The CD3-targeting antibody contains the amino acid sequence VH represented by any of SEQ ID NO: 43-55, and the amino acid sequence of VL represented by any of SEQ ID NO: 57-60. The bispecific antibody contains the first functional protein region comprising an antibody targeting CD3 and a second functional protein region. Dedicated nucleic acid, expression vector, genetically modified cell to produce an antibody, pharmaceutical composition and their use in the manufacture of a drug for the treatment of a tumour with CD3 as a target are also proposed.

EFFECT: antibody is able to bind to primate CD3, reduces the toxicity caused by cytokine release syndrome, and the resulting bispecific antibody is stable and has the ability to bind to T cells.

24 cl, 16 dwg, 15 tbl, 8 ex